![Henrik Elofsson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Henrik Elofsson
Keine laufenden Positionen mehr
Karriereverlauf von Henrik Elofsson
Ehemalige bekannte Positionen von Henrik Elofsson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MENDUS AB | Geschäftsführer | 01.07.2013 | - |
Arterion AB
![]() Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Direktor/Vorstandsmitglied | 03.09.2010 | - |
Gründer | 01.01.2007 | - | |
Corporate Officer/Principal | 03.09.2010 | 11.06.2013 |
Ausbildung von Henrik Elofsson
University of Linköping | Undergraduate Degree |
Chalmers School of Entrepreneurship | Graduate Degree |
Statistik
International
Schweden | 5 |
Operativ
Director/Board Member | 1 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MENDUS AB | Health Technology |
Private Unternehmen | 1 |
---|---|
Arterion AB
![]() Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Health Technology |
- Börse
- Insiders
- Henrik Elofsson
- Erfahrung